Wealthspire Advisors (New York)’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17M | Buy |
67,367
+14,821
| +28% | +$3.19M | 0.09% | 130 |
|
|
2026
Q1 | $11.4M | Sell |
52,546
-5,888
| -10% | -$1.31M | 0.09% | 107 |
|
|
2025
Q4 | $13.4M | Buy |
58,434
+8,053
| +16% | +$1.83M | 0.11% | 93 |
|
|
2025
Q3 | $11.7M | Sell |
50,381
-473
| -0.9% | -$96.3K | 0.06% | 107 |
|
|
2025
Q2 | $9.44M | Sell |
50,854
-2,888
| -5% | -$537K | 0.05% | 122 |
|
|
2025
Q1 | $11.3M | Sell |
53,742
-1,473
| -3% | -$286K | 0.07% | 104 |
|
|
2024
Q4 | $9.81M | Sell |
55,215
-539
| -1% | -$99.1K | 0.1% | 96 |
|
|
2024
Q3 | $11M | Buy |
55,754
+6,081
| +12% | +$1.13M | 0.11% | 93 |
|
|
2024
Q2 | $8.52M | Sell |
49,673
-3,615
| -7% | -$599K | 0.11% | 88 |
|
|
2024
Q1 | $9.7M | Sell |
53,288
-2,018
| -4% | -$348K | 0.13% | 76 |
|
|
2023
Q4 | $8.57M | Sell |
55,306
-177
| -0.3% | -$25.8K | 0.12% | 79 |
|
|
2023
Q3 | $8.27M | Buy |
55,483
+9,072
| +20% | +$1.33M | 0.14% | 77 |
|
|
2023
Q2 | $6.25M | Sell |
46,411
-551
| -1% | -$80.8K | 0.1% | 87 |
|
|
2023
Q1 | $7.48M | Sell |
46,962
-3,853
| -8% | -$589K | 0.13% | 80 |
|
|
2022
Q4 | $8.21M | Buy |
50,815
+2,578
| +5% | +$395K | 0.15% | 79 |
|
|
2022
Q3 | $6.47M | Buy |
48,237
+446
| +0.9% | +$64K | 0.14% | 81 |
|
|
2022
Q2 | $7.32M | Buy |
47,791
+3,153
| +7% | +$482K | 0.15% | 72 |
|
|
2022
Q1 | $7.24M | Sell |
44,638
-10,433
| -19% | -$1.52M | 0.16% | 57 |
|
|
2021
Q4 | $7.46M | Buy |
55,071
+35,007
| +174% | +$4.14M | 0.17% | 60 |
|
|
2021
Q3 | $2.16M | Buy |
20,064
+10,739
| +115% | +$1.23M | 0.04% | 159 |
|
|
2021
Q2 | $1.05M | Sell |
9,325
-27,263
| -75% | -$3.07M | 0.03% | 159 |
|
|
2021
Q1 | $3.96M | Buy |
36,588
+6,694
| +22% | +$716K | 0.09% | 106 |
|
|
2020
Q4 | $3.2M | Sell |
29,894
-11,565
| -28% | -$1.11M | 0.1% | 98 |
|
|
2020
Q3 | $3.63M | Buy |
41,459
+4,486
| +12% | +$422K | 0.22% | 56 |
|
|
2020
Q2 | $3.63M | Buy |
36,973
+3,980
| +12% | +$350K | 0.25% | 48 |
|
|
2020
Q1 | $2.51M | Buy |
32,993
+23,205
| +237% | +$1.98M | 0.11% | 108 |
|
|
2019
Q4 | $867K | Buy |
9,788
+1,245
| +15% | +$103K | 0.06% | 71 |
|
|
2019
Q3 | $647K | Buy |
8,543
+4,507
| +112% | +$309K | 0.05% | 69 |
|
|
2019
Q2 | $293K | Buy |
+4,036
| New | +$317K | 0.03% | 75 |
|
|
2019
Q1 | – | Sell |
-1,757
| Closed | -$162K | – | 50 |
|
|
2018
Q4 | $162K | Buy |
+1,757
| New | +$155K | 0.02% | 77 |
|
Other funds holding ABBV
Wealthspire Advisors (New York)'s ABBV Position: Q2 2026 in Review
Wealthspire Advisors (New York) increased its AbbVie (ABBV) stake by 28% in Q2 2026, buying an estimated $3.19M and bringing the position to 67,367 shares worth $17M. The position accounts for 0.09% of the portfolio, ranked #130.
Wealthspire Advisors (New York) first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Wealthspire Advisors (New York) held 67,367 shares of AbbVie worth $17M as of Q2 2026.
- Wealthspire Advisors (New York) bought 14,821 AbbVie shares in Q2 2026, an estimated $3.19M.
- AbbVie made up 0.09% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #130 holding.
- Wealthspire Advisors (New York) first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
- 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.